Treatment of Open-angle Glaucoma and Ocular Hypertension with Preservative-free Tafluprost/timolol Fixed-dose Combination Therapy: 6 Case Reports and Clinical Outcomes

Overview

Journal BMC Ophthalmol

Publisher Biomed Central

Specialty Ophthalmology

Date 2022 Apr 3

PMID 35366846

Authors

E Ansari

S Chappiti

J Pavicic-Astalos

J C Pinto-Bonilla

I Riva

M Sacchi

F Saenz-Frances

Affiliations

Soon will be listed here.

Abstract

Background: Treatment of open angle glaucoma (OAG) and/or ocular hypertension (OHT) focuses on achievement of target intraocular pressure (IOP), with the objective of slowing disease progression. However, ocular surface health is an important consideration in the optimization of treatment. We report 6 patient cases in which enhanced IOP control was achieved following appropriate management of ocular surface inflammation and a therapeutic switch to the preservative-free (PF) tafluprost (0.0015%)/timolol (0.5%) fixed-dose combination (FC).

Case Presentation: Six patient cases, aged 48-74 years, presented with OAG or OHT. Each patient had signs and symptoms of ocular surface disease (OSD). Cases 1-3 were each receiving maximal medical therapy for OAG; regimens comprising prostaglandin analogue (PGA), β-blocker, carbonic anhydrase inhibitor (CAI) and α-2 agonist agents (including treatments containing preservative agent). Cases 1 and 2 reported IOP values ≥23 mmHg in each eye, and wide IOP fluctuations were identified when reviewing patient data concerning case 3 (11-20 mmHg). Maximal therapy was ceased and PF tafluprost/timolol FC was initiated, after which the signs and symptoms of OSD were improved and IOP was reduced (≤18 mmHg for cases 1-3) and stabilized. Cases 4 and 5 were diagnosed with OAG and case 6 had OHT. Each had symptoms and signs of OSD and were treated with a preserved PGA monotherapy (latanoprost 0.005% or bimatoprost 0.03%). At presentation, IOP was 24 mmHg in both eyes (case 4), ≥18 mmHg (case 5) and ≥ 22 mmHg (case 6). Following a switch to the PF tafluprost/timolol FC, OSD symptoms were improved and IOP was 14 mmHg (both eyes; case 4), ≤14 mmHg (case 5) and 16 mmHg (both eyes; case 6).

Conclusions: In addition to IOP-lowering efficacy, approaches to the management of OAG and OHT should consider the impact of treatment tolerability and the susceptibility of these patients to OSD. The presence of ocular surface inflammation appears to be detrimental to adherence and therefore to the effectiveness of topical medications. Addressing OSD through the use of PF FC formations, such as the PF tafluprost/timolol FC, reduces exposure to potentially toxic agents and facilitates improvements in IOP control.

Citing Articles

Evidence in Practice: A Review of Real-Life Studies and Clinical Experience with the Preservative-Free Tafluprost (0.0015%) and Timolol (0.5%) Fixed-Dose Combination.

Hollo G Clin Ophthalmol. 2024; 18:3185-3196.

PMID: 39534090 PMC: 11556326. DOI: 10.2147/OPTH.S479852.

The Role and Mechanism of Nicotinamide Riboside in Oxidative Damage and a Fibrosis Model of Trabecular Meshwork Cells.

Zeng Y, Lin Y, Yang J, Wang X, Zhu Y, Zhou B Transl Vis Sci Technol. 2024; 13(3):24.

PMID: 38546981 PMC: 10981432. DOI: 10.1167/tvst.13.3.24.

References

Matlach J, Bender S, Konig J, Binder H, Pfeiffer N, Hoffmann E . Investigation of intraocular pressure fluctuation as a risk factor of glaucoma progression. Clin Ophthalmol. 2018; 13:9-16. PMC: 6302802. DOI: 10.2147/OPTH.S186526. View

Friedman D, Hahn S, Gelb L, Tan J, Shah S, Kim E . Doctor-patient communication, health-related beliefs, and adherence in glaucoma results from the Glaucoma Adherence and Persistency Study. Ophthalmology. 2008; 115(8):1320-7, 1327.e1-3. DOI: 10.1016/j.ophtha.2007.11.023. View

Kurysheva N . Assessment of the optic nerve head, peripapillary, and macular microcirculation in the newly diagnosed patients with primary open-angle glaucoma treated with topical tafluprost and tafluprost/timolol fixed combination. Taiwan J Ophthalmol. 2019; 9(2):93-99. PMC: 6557063. DOI: 10.4103/tjo.tjo_108_17. View

Dempster M, McCorry N, Donnelly M, Barton K, Azuara-Blanco A . Individualisation of glaucoma quality of life measures: a way forward?. Br J Ophthalmol. 2019; 103(3):293-295. DOI: 10.1136/bjophthalmol-2019-313873. View

Quaranta L, Riva I, Gerardi C, Oddone F, Floriani I, Konstas A . Quality of Life in Glaucoma: A Review of the Literature. Adv Ther. 2016; 33(6):959-81. PMC: 4920851. DOI: 10.1007/s12325-016-0333-6. View

Osborne S, Montgomery D, Morris D, McKay I . Alphagan allergy may increase the propensity for multiple eye-drop allergy. Eye (Lond). 2004; 19(2):129-37. DOI: 10.1038/sj.eye.6701441. View

Perez-Bartolome F, Martinez-de-la-Casa J, Arriola-Villalobos P, Fernandez-Perez C, Polo V, Garcia-Feijoo J . Ocular Surface Disease in Patients under Topical Treatment for Glaucoma. Eur J Ophthalmol. 2017; 27(6):694-704. DOI: 10.5301/ejo.5000977. View

Bourne R, Kaarniranta K, Lorenz K, Traverso C, Vuorinen J, Ropo A . Changes in ocular signs and symptoms in patients switching from bimatoprost-timolol to tafluprost-timolol eye drops: an open-label phase IV study. BMJ Open. 2019; 9(4):e024129. PMC: 6500185. DOI: 10.1136/bmjopen-2018-024129. View

Rossi G, Pasinetti G, Scudeller L, Radaelli R, Bianchi P . Do adherence rates and glaucomatous visual field progression correlate?. Eur J Ophthalmol. 2010; 21(4):410-4. DOI: 10.5301/EJO.2010.6112. View

10.

Leung E, Medeiros F, Weinreb R . Prevalence of ocular surface disease in glaucoma patients. J Glaucoma. 2008; 17(5):350-5. DOI: 10.1097/IJG.0b013e31815c5f4f. View

11.

Prum Jr B, Rosenberg L, Gedde S, Mansberger S, Stein J, Moroi S . Primary Open-Angle Glaucoma Preferred Practice Pattern(®) Guidelines. Ophthalmology. 2015; 123(1):P41-P111. DOI: 10.1016/j.ophtha.2015.10.053. View

12.

Pisella P, Pouliquen P, Baudouin C . Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication. Br J Ophthalmol. 2002; 86(4):418-23. PMC: 1771067. DOI: 10.1136/bjo.86.4.418. View

13.

Boso A, Gasperi E, Fernandes L, Costa V, Alves M . Impact of Ocular Surface Disease Treatment in Patients with Glaucoma. Clin Ophthalmol. 2020; 14:103-111. PMC: 6969675. DOI: 10.2147/OPTH.S229815. View

14.

Aguayo Bonniard A, Yeung J, Chan C, Birt C . Ocular surface toxicity from glaucoma topical medications and associated preservatives such as benzalkonium chloride (BAK). Expert Opin Drug Metab Toxicol. 2016; 12(11):1279-1289. DOI: 10.1080/17425255.2016.1209481. View

15.

Rossi G, Pasinetti G, Scudeller L, Raimondi M, Lanteri S, Bianchi P . Risk factors to develop ocular surface disease  in treated glaucoma or ocular hypertension patients. Eur J Ophthalmol. 2013; 23(3):296-302. DOI: 10.5301/ejo.5000220. View

16.

Takagi Y, Osaki H, Yamashita T, Kai Y . Prospective Observational Post-marketing Study of Tafluprost 0.0015%/Timolol 0.5% Combination Ophthalmic Solution for Glaucoma and Ocular Hypertension: Short-Term Efficacy and Safety. Ophthalmol Ther. 2016; 5(2):191-206. PMC: 5125119. DOI: 10.1007/s40123-016-0057-3. View

17.

Sleath B, Blalock S, Carpenter D, Sayner R, Muir K, Slota C . Ophthalmologist-patient communication, self-efficacy, and glaucoma medication adherence. Ophthalmology. 2014; 122(4):748-54. PMC: 4994530. DOI: 10.1016/j.ophtha.2014.11.001. View

18.

Gray T, Fenerty C, Harper R, Spencer A, Campbell M, Henson D . Individualised patient care as an adjunct to standard care for promoting adherence to ocular hypotensive therapy: an exploratory randomised controlled trial. Eye (Lond). 2011; 26(3):407-17. PMC: 3299012. DOI: 10.1038/eye.2011.269. View

19.

Aptel F, Denis P . Balancing efficacy and tolerability of prostaglandin analogues and prostaglandin-timolol fixed combinations in primary open-angle glaucoma. Curr Med Res Opin. 2011; 27(10):1949-58. DOI: 10.1185/03007995.2011.613923. View

20.

Pfeiffer N, Traverso C, Lorenz K, Saarela V, Liinamaa J, Uusitalo H . A 6-month study comparing efficacy, safety, and tolerability of the preservative-free fixed combination of tafluprost 0.0015% and timolol 0.5% versus each of its individual preservative-free components. Adv Ther. 2014; 31(12):1228-46. PMC: 4271134. DOI: 10.1007/s12325-014-0163-3. View